Abstract:Niemann-Pick disease type C1 (NPC1) is a fatal congenital neurodegenerative disorder caused by mutations in the NPC1 gene, which is involved in cholesterol transport in lysosomes. Broad clinical manifestations of NPC1 include liver failure, pulmonary disorder, neurological deficits, and psychiatric symptoms. The main cause of death in NPC1 patients involves central nervous system (CNS) dysfunction; there is no essential treatment. We generated a tyrosine-mutant adeno-associated virus (AAV) 9/3 vector that expresses human NPC1 under a CMV promotor (AAV-CMV-hNPC1) and injected it into the left lateral ventricle (5 μl) and cisterna magna (10 μl) of Npc1 homo-knockout (Npc1-/-) mice. Each mouse received total 1.35×1011 vector genome on day 4 or 5 of life. AAV-treated Npc1-/- mice (n=11) had an average survival of >28 weeks, while all saline-treated Npc1-/- mice (n=11) and untreated Npc1-/- mice (n=6) died within 16 weeks. Saline-treated and untreated Npc1-/- mice lost body weight from seven weeks until death. However, the average body weight of AAV-treated Npc1-/- mice increased until 15 weeks. AAV-treated Npc1-/- mice also showed a significant improvement in Rotarod test performance. A pathological analysis at 11 weeks showed that cerebellar Purkinje cells were preserved in AAV-treated Npc1-/- mice. In contrast, untreated Npc1-/- mice showed an almost total loss of cerebellar Purkinje cells. Combined injection into both the lateral ventricle and cisterna magna achieved broader delivery of the vector to the CNS, leading to better outcomes than noted in previous reports with injection into the lateral ventricles or veins alone. In AAV-treated Npc1-/- mice, vector genome DNA was detected widely in the CNS and liver. Human NPC1 RNA was detected in the brain, liver, lung, and heart. Accumulated unesterified cholesterol in liver was reduced in the AAV-treated Npc1-/- mice. Our results suggest the feasibility of gene therapy for patients with NPC1.

Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency

Gene therapy corrects the neurological deficits of mice with sialidosis

AAV-mediated expression of mouse or human GLDC normalises metabolic biomarkers in a GLDC-deficient mouse model of Non-Ketotic Hyperglycinemia

Liver-directed Gene Therapy Corrects Neurologic Disease in a Murine Model of Mucopolysaccharidosis Type I-Hurler

A blood-brain-barrier penetrant AAV gene therapy rescues neurological deficits in mucolipidosis IV mice

A blood-brain-barrier penetrant AAV gene therapy improves neurologic function in symptomatic mucolipidosis IV mice.

Optimization of systemic AAV9 gene therapy in Niemann-Pick disease type C1 mice

Gene Therapy in a Mouse Model of Niemann–Pick Disease Type C1

Liver-Directed Neonatal Gene Therapy Prevents Cardiac, Bone, Ear, and Eye Disease in Mucopolysaccharidosis I Mice

Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46-/- mice.

Gene therapy restores mitochondrial function and protects retinal ganglion cells in optic neuropathy induced by a mito-targeted mutant ND1 gene

Gene delivery corrects N-acetylglutamate synthase deficiency and enables insights in the physiological impact of L-arginine activation of N-acetylglutamate synthase

An in vitro and in vivo efficacy evaluation of a novel gene therapy candidate (SBT101) in mouse models of adrenomyeloneuropathy and in NHPs

Restoration of defective oxidative phosphorylation to a subset of neurons prevents mitochondrial encephalopathy

Decreasing ganglioside synthesis delays motor and cognitive symptom onset in knockout mice

Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency

Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice

A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency

Development of new NGLY1 assay systems - toward developing an early screening method for NGLY1 deficiency

Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells

Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE